Overview

Oral Azithromycin to Prevent Stillbirths and Infant Mortality in Mali

Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The double blind randomized controlled trial will assess the efficacy of oral azithromycin administered to pregnant women and/or infants during routine care in preventing stillbirths and mortality through 6-12 months of age in Mali, West Africa, where rates of infant and under five mortality are among the highest in the world.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland
University of Maryland, Baltimore
Collaborator:
Bill and Melinda Gates Foundation
Treatments:
Azithromycin